Oral aripiprazole (Abilify®) is an atypical antipsychotic agent that is approved worldwide for
use in adult patients with schizophrenia. It is a quinolinone derivative that has a unique …

Aripiprazole, a quinolinone derivative, is an atypical antipsychotic drug indicated for the
treatment of adult patients with schizophrenia. Aripiprazole 10 or 15mg once daily is …

Background: During the past decade, there has been some progress in the
pharmacotherapy of schizophrenia and schizoaffective disorder. Current evidence supports …

Aripiprazole (Abilify®) is an atypical antipsychotic drug that has been recently introduced for
clinical use in the treatment of schizophrenia. Aripiprazole has a unique pharmacologic …

Aripiprazole is a novel antipsychotic with a unique mechanism of action. Presented here is a
pooled analysis of safety and tolerability data from all completed short-term, placebo …

Aripiprazole is an atypical antipsychotic that has been shown to be more effective than
placebo and at least as effective as haloperidol and risperidone in the treatment of …

Introduction Aripiprazole is a third generation antipsychotic approved by the US Food and
Drug Administration (FDA) for the treatment of schizophrenia. Aripiprazole is available as …

Introduction: Aripiprazole, a dopamine D2 receptor partial agonist, has also partial agonist
activity at serotonin (5-HT) 1A receptors and antagonist activity at 5-HT2A receptors …

It seems that the efficacy of aripiprazole for treating schizophrenia is mediated through a
combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and …

Aims: To date there have been no reports of long‐term efficacy of aripiprazole in Asian
populations. The aim of the present study was therefore to investigate the long‐term efficacy …